PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stemcells, but minoxidil and finasteride are still the main treatments.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stemcells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.
Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
User regrew lost hair using microneedling, minoxidil, finasteride, Nizoral, fish oil, and collagen peptide. Progress was slow but constant, and patience was important.